Mineralocorticoid receptor blockade: New insights into the mechanism of action in patients with cardiovascular disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 4, Issue 3, 2003, Pages 164-168

  Pitt, Bertram ^a,c   Stier Jr , Charles T ^b   Rajagopalan, Sanjay ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aldosterone cortisol; Heart failure; Myocardial infarction; Systolic left ventricular dysfunction

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTERONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPIDERMAL GROWTH FACTOR; EPLERENONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID ANTAGONIST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OSTEOPONTIN; PLACEBO; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; AUTONOMIC INNERVATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FIBRINOLYSIS; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; NATRIURESIS; NONHUMAN; RECEPTOR BLOCKING; REVIEW; VALVULAR HEART DISEASE;

EID: 0242608659     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2003.025     Document Type: Review

References (67)

1. Pitt B, Zannad F, Remme W et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709.
2. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
3. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to highdose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A.
4. Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 1986;9:63-76.
5. Cody RJ, Pitt B, Perez A, Bettman R. The benefit of spironolactone in the RALES Trial is not primarily due to a diuretic effect. J Am Coll Cardiol 2000;35:212A.
6. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2000;345:1689-97.
7. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-06.
8. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-E662.
9. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
10. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-5.
11. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin sci (Lond) 1998;95:687-92.
12. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:336-44.
13. Brown NJ, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-27.
14. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
15. Funder JW, Pearce PT, Smith R, Campbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid, receptors. Endocrinology 1989;125:2224-6.
16. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-10.
17. Hatakeyama H, Miyamori I, Takeda Y, Yamamoto H, Mabuchi H. The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 1996;40:639-45.
18. Takeda Y, Miyamori I, Inaba S et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29:45-8.
19. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
20. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000;85:2519-25.
21. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
22. Pitt B. "Escape" of aldosterone production inpatients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovascular Drugs & Therapy 1995;9:145-9.
23. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
24. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators [see comments]. Circulation 1999; 100: 1056-64.
25. Cicoira M, Zanolla L, Rossi A et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-12.
26. Quinn S, Williams G. Regulation of aldosterone secretion. Annu Rev Physiol 1988;50:409-26.
27. Aguilera G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. J Steroid Biochem Mol Blot 1993;45:147-51.
28. Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC. Endothelin-1 and the adrenal gland. J Cardiovascular Pharmacol 2000;35:S17-S20.
29. Guillon G, Trueba M, Joubert D et al. Vasopressin Stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology 1995; 136:1285-95.
30. Okubo S, Niimura F, Nishimura H et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99: 855-60.
31. Harada E, Yoshimura M, Yasue H et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
32. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001;37:1444-9.
33. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76: 1259-65.
34. Liu YJ, Nakagawa Y, Toya K et al. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int 2000; 57:2064-71.
35. Oitt B, Reichek N, Metscher B et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy for essential hypertension and left ventricular hypertrophy: The 4E Study. In: American College of Cardiology. Atlanta, GA; Circulation 2002: in press.
36. Heiniger CD, Kostadinova RM, Rochat MK et al. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. Faseb J 2003;17:917-19.
37. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998;31:451-8.
38. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232-7.
39. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension 2001;37:594-8.
40. Stier Jr CT, Zuckerman A, Harashima H, Chander P. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats. 18th Scientific Meeting of the International Society of Hypertension, Chicago, IL. 2000;5:5-75.
41. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation 2002;105:2212-16.
42. Bauersachs J, Heck M, Fraccarollo D et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction; Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39:351-8.
43. Natarajan R, Lanting L, Bai W, Bravo EL, Nadler J. The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. J Steroid Biochem Mol Biol 1997;61:47-53.
44. Hanke CJ, O'Brien T, Pritchard KA, Campbell WB. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 2000;35:324-8.
45. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998;32:527-33.
46. Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001;19:635-9.
47. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 2001;24:116-23.
48. Ni Z, Vaziri ND. Effect of salt loading on nitric oxide synthase expression in normotensive rats. Am J Hypertens 2001; 14:155-63.
49. Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 2001;37:856-61.
50. Blasi ER, Friedrich GE, De Ciechi PA et al. Aldosterone/salt-induced myocardial injury: a vascular inflammatory disease. Am J Hypertens 2001;14:8A-9A.
51. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000;35:1078-84.
52. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regal Integr Comp Physiol 2001;281:R944-R950.
53. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
54. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15:264-72.
55. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-52.
56. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plaminogen activator-1 production. J Clin Endocrinology Metab 2000;95:336-44.
57. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001;87:18C-24C.
58. Navier W. The inotropic action of d-aldosterone on papillary muscles isolated from monkey. J Pharmacol Exp Ther 1965;148:215-17.
59. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-07.
60. Chowdhary S, Vaile JC, Fletcher J, Ross HF, Coote JH, Townend JN. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264-9.
61. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995;77:841-8.
62. Silvestre J-S, Heymes C, Oubenaissa A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
63. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003:107:2559-65.
64. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-6.
65. Kasama S, Toyama T, Kumakura H et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
66. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
67. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.